AtomVie Global Radiopharma and ITM Isotope Technologies Munich SE have signed a supply agreement for non-carrier-added lutetium-177, a radioisotope used in targeted cancer therapies. ITM will supply the isotope to support AtomVie’s contract development and manufacturing work for radiopharmaceutical companies.
The agreement expands access to the isotope for companies working with AtomVie on precision oncology programs. AtomVie CEO Bruno Paquin said the supply arrangement will support therapeutic and diagnostic development programs for the contract manufacturer’s current and future customers.
ITM’s lutetium-177 is designed to be attached to molecules that carry the isotope to tumor sites. Once delivered to a tumor, the isotope emits beta radiation that can kill cancer cells. ITM holds a Drug Master File with the U.S. Food and Drug Administration for its non-carrier-added lutetium-177 and has marketing authorization in the European Union under the brand name EndolucinBeta.
AtomVie is commissioning a 72,300-square-foot facility in Hamilton, Ontario. The company provides process and analytical method development, manufacturing under good manufacturing practice standards, and quality control for radiopharmaceutical developers. Its services also include regulatory support and distribution of clinical and commercial drug products.
ITM develops, produces and supplies medical radioisotopes and is developing its own radiopharmaceutical treatments and diagnostics for hard-to-treat tumors. Its oncology pipeline includes multiple Phase 3 studies of candidates that combine medical radioisotopes with targeting molecules.